Do you love radiopharmaceuticals as much as we do? CPDC is always looking for exceptional people to strengthen our team. If you are interested in joining our team or if you would like to learn more about our current or future opportunities please contact email@example.com. Check our list of current opportunities below
The Centre for Probe Development and Commercialization (CPDC) is dedicated to fostering the development, translation, and commercialization of molecular imaging probes, radiopharmaceuticals and associated technologies. The Centre is seeking outstanding applicants for a Research Associate I – Biology to support ongoing or new CPDC initiatives, or those of contract clients.Learn more
This position is responsible for technical leadership and project management of CDMO (Contract, Development & Manufacturing Organization) programs. The role will work in collaboration with team members, other departments and customers to ensure successful development, setup, launch and routine manufacturing of radiopharmaceuticals.Learn more
The Centre for Probe Development and Commercialization (CPDC) is dedicated to fostering the development, translation, and commercialization of molecular imaging probes and associated technologies. The Centre is seeking outstanding applicants for a Production Technologist. This position is located in Hamilton, ON.Learn more
The Centre for Probe Development and Commercialization (CPDC) is dedicated to fostering the development, translation, and commercialization of molecular imaging probes and associated technologies.
As a QC Technician, you will be responsible for working in accordance with company policy and within GMPs while contributing your technical expertise to support current products and develop future drugs within the CPDC portfolio. This position is located in Hamilton, Ontario.
This position is responsible for planning, leading and supporting all key HR areas including recruitment and selection, employee relations and engagement, training and development, performance management, compensation and benefits, and policies/procedures. This is a hands on and stand-alone HR role requiring a versatile and flexible individual comfortable in a dynamic and changing business environment.Learn more
FACIT and Fusion Pharmaceuticals (“Fusion”) announced an investment to support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.